Multidimensional analysis of clinical symptoms in patients with Fabry's disease

International Journal of Clinical Practice

Volumn 67, Issue 2, 2013, Pages 120-127

  Kaminsky, P ^a   Noel, E ^b   Jaussaud, R ^c   Leguy Seguin, V ^d   Hachulla, E ^e   Zenone, T ^f   Lavigne, C ^g   Marie, I ^h   Maillot, F ⁱ   Masseau, A ^j   Serratrice, C ^k   Lidove, O ^l  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c REIMS UNIVERSITY HOSPITAL   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

^e UNIV LILLE   (France)

^f CENTRE HOSPITALIER DE VALENCE   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h ROUEN UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF TOURS   (France)

^j HÔTEL DIEU   (France)

^k HÔPITAL SAINT JOSEPH   (France)

^l GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACROPARESTHESIA; ADULT; AGE; ARTICLE; CEREBROVASCULAR ACCIDENT; CLUSTER ANALYSIS; CORNEA DISEASE; CORNEA VERTICILLATA; DISEASE COURSE; DISEASE SEVERITY; DYSHIDROSIS; EXERCISE TOLERANCE; FABRY DISEASE; FEMALE; FRANCE; GASTROINTESTINAL DISEASE; HEARING IMPAIRMENT; HEART DISEASE; HEMANGIOKERATOMA; HIERARCHICAL ASCENDANT CLASSIFICATION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CORRESPONDENCE ANALYSIS; MULTIVARIATE ANALYSIS; PARESTHESIA; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SENSIBILITY;

ADOLESCENT; ADULT; AGE OF ONSET; BRAIN DISEASES; CHILD; CHILD, PRESCHOOL; FABRY DISEASE; FEMALE; HEARING LOSS; HEART DISEASES; HUMANS; KIDNEY DISEASES; MALE; RISK FACTORS; SEX FACTORS; YOUNG ADULT;

EID: 84872312308     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12016     Document Type: Article

References (29)

1. Zarate YA, Hopkin RJ,. Fabry's disease. Lancet 2008; 372: 1427-35.
2. Brady RO, Murray GJ, Moore DF, Schiffmann R,. Enzyme replacement therapy in Fabry disease. J Inherit Metab Dis 2001; 24 (Suppl. 2): 18-24.
3. Desnick RJ, Brady R, Barranger J, et al., Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138: 338-46.
4. Maron BJ, McKenna WJ, Danielson GK, et al., CC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines (Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy). Eur Heart J 2003; 24: 1965-91.
5. Benzécri JP,. L'Analyse des données, Tome 1: La taxinomie, Tome 2: l'analyse des correspondances, 2nd edn. Paris: Dunod, 1976.
6. Greenacre MJ,. Correspondence analysis in medical research. Stat Methods Med Res 1992; 1: 97-117.
7. Lebart L, Morineau A, Piron M,. Statistique exploratoire multidimensionnelle, 3rd edn. Paris: Dunod, 2000.
8. Deegan PB, Baehner AF, Barba Romero MA, et al., Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006; 43: 347-52.
9. Eng CM, Fletcher J, Wilcox WR, et al., Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007; 30: 184-92.
10. Hoffmann B, Beck M, Sunder-Plassmann G, et al., Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy-a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 2007; 23: 535-42.
11. MacDermot KD, Holmes A, Miners AH,. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38: 769-75.
12. MacDermot KD, Holmes A, Miners AH,. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38: 750-60.
13. Vedder AC, Linthorst GE, van Breemen MJ, et al., The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 2007; 30: 68-78.
14. Gupta S, Ries M, Kotsopoulos S, Schiffmann R,. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore) 2005; 84: 261-8.
15. Orteu CH, Jansen T, Lidove O, et al., Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol 2007; 157: 331-7.
16. Galanos J, Nicholls K, Grigg L, et al., Clinical features of Fabry's disease in Australian patients. Intern Med J 2002; 32: 575-84.
17. Hoffmann B, Keshav S,. Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment. Acta Paediatr Suppl 2007; 96: 84-6.
18. Mehta A, Clarke JT, Giugliani R, et al., Natural course of Fabry disease: changing pattern of causes of death in FOS-Fabry Outcome Survey. J Med Genet 2009; 46: 548-52.
19. Nguyen TT, Gin T, Nicholls K, et al., Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Experiment Ophthalmol 2005; 33: 164-8.
20. Sodi A, Ioannidis AS, Mehta A, et al., Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey. Br J Ophthalmol 2007; 91: 210-4.
21. Orssaud C, Dufier J, Germain D,. Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Ophthalmic Genet 2003; 24: 129-39.
22. Keilmann A, Hegemann S, Conti G, Hajioff D,. Fabry disease and the ear. In:, Mehta A, Beck M, Sunder-Plassman G, eds. Fabry Disease: Perspectives from 5 years of FOS. Oxford: Oxford Pharmagenesis, 2006. Available from: http://www.ncbi.nlm.nih.gov/books/NBK11606/.
23. Conti G, Sergi B,. Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females. Acta Paediatr Suppl 2003; 92: 33-7.
24. Germain DP, Avan P, Chassaing A, Bonfils P,. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet 2002; 3: 10.
25. Ries M, Kim HJ, Zalewski CK, et al., Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain 2007; 130: 143-50.
26. Beer M, Weidemann F, Breunig F, et al., Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 2006; 97: 1515-8.
27. Weidemann F, Niemann M, Breunig F, et al., Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009; 119: 524-9.
28. Schachern PA, Shea DA, Paparella MM, Yoon TH,. Otologic histopathology of Fabry's disease. Ann Otol Rhinol Laryngol 1989; 98: 359-63.
29. Beck M,. The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease. Acta Paediatr Suppl 2006; 95: 43-6.